NCT04445844View on ClinicalTrials.gov

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8Triple-negative Breast Cancer
Interventions
BIOLOGICAL

Pelareorep

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Retifanlimab

Given IV

Trial Locations (2)

43212

The Ohio State University Stefanie Spielman Comprehensive Breast Center, Columbus

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

Oncolytics Biotech

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Mridula George, MD

OTHER